Nucleai develops spatial AI that analyzes pathology images and spatial data at the cellular and tissue levels to map cellular interactions and predict treatment responses. Its platform extracts detailed patterns from biopsies to inform biomarker discovery, drug development, and therapeutic targeting, with applications in immunotherapies, antibody‑drug conjugates (ADCs), and bi‑specifics. The company is deploying AI algorithms for prospective patient enrollment in clinical trials, a capability described in the article as a first‑in‑field approach to personalized medicine. Nucleai reports collaborations with over 60% of the top 20 biopharma companies and positions its technology as an AI‑enabled companion diagnostic to guide trial selection and treatment strategies. The company is headquartered in Israel and Chicago. Financially, it secured a $14 million investment led by M Ventures that supports scaling and clinical deployment, bringing total funding to $60 million. Nucleai is an AI-powered spatial biology company that leverages pathology data to inform drug development and clinical decision-making. Its platform combines artificial intelligence, big data, and spatial biology to make spatial analysis scalable and operational across large pathology data sets. Customers include leading pharmaceutical companies, contract research organizations, and diagnostics laboratories applying the platform in translational research, clinical trials, patient stratification, biomarker discovery, target identification, and companion diagnostic development. Nucleai plans to further develop its platform and expand its commercial footprint across biopharmaceutical companies and CROs, supporting both retrospective and prospective analyses in clinical trials. Financially, the company has raised close to $50 million since being founded four years ago, including a newly closed $33 million Series B. Investor representatives Andy Harrison and Cris De Luca will join the board, and Section 32’s Michael Pellini will join as an observer.

Total raised

$47M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2024